However, no significant differences in CR/CRi rates were observed between subgroups without corresponding co‐mutation and those with co‐mutation, including TET1/2, IDH1/2, MDS‐related genes, FLT3‐TKD, and GATA2 after the first cycle of induction chemotherapy (Figure 3A). This evidence concerns the gene FLT3 and myelodysplastic syndrome.